<DOC>
	<DOCNO>NCT01977651</DOCNO>
	<brief_summary>The objective study evaluate incidence seizure monitor safety enzalutamide treatment subject metastatic castration-resistant prostate cancer know risk factor ( ) seizure .</brief_summary>
	<brief_title>A Study Evaluate Potential Increased Risk Seizures Among Metastatic Castration-Resistant Prostate Cancer ( mCRPC ) Patients Treated With Enzalutamide</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Seizures</mesh_term>
	<criteria>Subject histologically confirm metastatic adenocarcinoma prostate . Subject ongoing androgen deprivation therapy Gonadotropinreleasing hormone ( GnRH ) analogue ( agonist antagonist ) bilateral orchiectomy ( i.e. , surgical medical castration ) . Subject disease progression least one following : 1 . ProstateSpecific Antigen ( PSA ) progression define minimum 2 rise PSA level interval least 1 week draw ; 2 . Bone disease progression define Prostate Cancer Working Group 2 guideline ( least 2 new lesion ) bone scan ; 3 . Soft tissue disease progression define RECIST 1.1 For subject orchiectomy , must plan maintain effective GnRHanalogue therapy duration study . Subject must fail least one course androgen deprivation therapy ( ADT ) , i.e. , treatment GnRH analogue . Subject Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Subject evaluate local neurologist prior study entry determine subject least one risk factor seizure include : 1. past history seizure due cause except single febrile seizure childhood . Patients history seizures seizure within 12 month Screening must anticonvulsant 12 month prior Screening , 2. history cerebrovascular accident ( CVA ) transient ischemic attack ( TIA ) , 3. history traumatic brain head injury loss consciousness 4. unexplained loss consciousness within last 12 month , 5. presence space occupy lesion brain include previously treat brain metastasis ( e ) primary central nervous system ( CNS ) tumor , 6. history arteriovenous malformation brain , 7. history brain infection ( i.e. , abscess , meningitis , encephalitis ) , 8. current use medication may lower seizure threshold 9. presence Alzheimer 's disease , meningioma , leptomeningeal disease prostate cancer . Subject able swallow study drug comply study requirement . Subject agree participate another interventional study treatment . Male subject female partner childbearing potential must use two acceptable method birth control ( one must include condom barrier method contraception ) start Screening continue throughout study period 3 month final study drug administration . 1 . Two acceptable form birth control include : 1 . Condom ( barrier method contraception ) , AND 2 . One follow acceptable form contraception require : 1 . Established use oral , injected implant hormonal method contraception . 2 . Placement intrauterine device ( IUD ) intrauterine system ( IUS ) . 3 . Barrier method contraception : Occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository ) . 4 . Vasectomy surgical castration least 6 month prior Screening . Male subject must use condom , sex pregnant woman . Male subject must donate sperm start Screening throughout study period least 3 month final drug administration . Subject history exposure enzalutamide . Subject severe concurrent disease , infection , comorbidity , judgment Investigator , would make subject inappropriate enrollment . Subject currently treat antiepileptic . Subject history seizure within past 12 month Screening assessed neurology examination history . Subject rapidly progress visceral disease receive think able tolerate cytotoxic chemotherapy . ( However , subject previously receive cytotoxic chemotherapy permit ) . Subject clinical sign suggestive high imminent risk pathological fracture , spinal cord compression and/or cauda equina syndrome . Subject 's absolute neutrophil count &lt; 1500/microliter ( µL ) , platelet count &lt; 100,000/µL ) hemoglobin &lt; 5.6 millimoles ( mmol ) /liter ( L ) ( 9 gram ( g ) /deciliter ( dL ) Screening . Subject 's total bilirubin ≥ 1.5 x upper limit normal ( ULN ) ( except subject document Gilbert 's disease ) alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≥ 2.5x upper limit normal ( ULN ) Screening . Subject 's estimate creatinine clearance ( Cer ) less 30 milliliter ( mL ) /minute ( min ) Cockcroft Gault formula ( Creatinine Clearance ( mL/min ) = ( 140 age ) ( weight ( wt ) kilogram ( kg ) / 72 x serum creatinine ( milligram ( mg ) /100 mL ) [ Cockcroft , 1976 ] Screening . Subject uncontrolled hypertension indicate rest systolic blood pressure &gt; 160 millimeter mercury ( mmHg ) diastolic blood pressure &gt; 100 millimeter mercury ( mmHg ) Screening . Subject receive investigational agent within 4 week 5 half life whichever longer prior Day 1 . Subject show hypersensitivity reaction active pharmaceutical ingredient capsule component , include Labrasol , butylate hydroxyanisole , butylate hydroxytoluene .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>enzalutamide</keyword>
	<keyword>Xtandi</keyword>
	<keyword>seizure</keyword>
	<keyword>Central Nervous System</keyword>
	<keyword>MDV3100</keyword>
	<keyword>metastatic castration-resistant prostate cancer ( mCRPC )</keyword>
</DOC>